Form 8-K - Current report:
SEC Accession No. 0001731122-24-001838
Filing Date
2024-11-20
Accepted
2024-11-20 06:06:05
Documents
14
Period of Report
2024-11-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6160_8k.htm   iXBRL 8-K 32211
2 EXHIBIT 10.1 e6161_ex10-1.htm EX-10.1 31755
  Complete submission text file 0001731122-24-001838.txt   247370

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE vrpx-20241118.xsd EX-101.SCH 3027
4 XBRL LABEL FILE vrpx-20241118_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE vrpx-20241118_pre.xml EX-101.PRE 24173
16 EXTRACTED XBRL INSTANCE DOCUMENT e6160_8k_htm.xml XML 3810
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

EIN.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 241478125
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)